AbCellera Biologics Inc
For the period ended Jun 30, 2024. Filed Aug 6, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 6, 2024
ABCL$12.46-0.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
| Common Shares · AdditionalPaid-in Capital · Accumulated Earnings · AccumulatedOtherComprehensiveLoss · TotalShareholders'Equity | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Shares · Amount | |||||||||
| Balances as of December 31, 2023 | 290,824,970 | $753,199 | $121,052 | $279,787 | $(1,720) | $1,152,318 | |||
| Shares issued and restricted stock units ("RSUs") vested under stock option plan | 2,796,342 | 11,363 | (10,471) | – | – | 892 | |||
| Stock-based compensation expense | – | – | 17,409 | – | – | 17,409 | |||
| Foreign currency translation adjustment | – | – | – | – | (96) | (96) | |||
| Net loss | – | – | – | (40,610) | – | (40,610) | |||
| Balances as of March 31, 2024 | 293,621,312 | $764,562 | $127,990 | $239,177 | $(1,816) | $1,129,913 | |||
| Shares issued and restricted stock units ("RSUs") vested under stock option plan | 1,044,220 | 5,404 | (4,944) | – | – | 460 | |||
| Stock-based compensation expense | – | – | 17,782 | – | – | 17,782 | |||
| Foreign currency translation adjustment | – | – | – | – | (257) | (257) | |||
| Net loss | – | – | – | (36,930) | – | (36,930) | |||
| Balances as of June 30, 2024 | 294,665,532 | $769,966 | $140,828 | $202,247 | $(2,073) | $1,110,968 | |||
| Common Shares · AdditionalPaid-in Capital · Accumulated Earnings · AccumulatedOtherComprehensiveLoss · TotalShareholders'Equity | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares · Amount | ||||||||||||
| Balances as of December 31, 2022 | 286,851,595 | $734,365 | $74,118 | $426,185 | $(1,391) | $1,233,277 | ||||||
| Shares issued and restricted stock units ("RSUs") vested under stock option plan | 1,574,919 | 8,451 | (7,962) | – | – | 489 | ||||||
| Share-based compensation expense | – | – | 15,474 | – | – | 15,474 | ||||||
| Foreign currency translation adjustment | – | – | – | – | (630) | (630) | ||||||
| Net loss | – | – | – | (40,110) | – | (40,110) | ||||||
| Balances as of March 31, 2023 | 288,426,514 | $742,816 | $81,630 | $386,075 | $(2,021) | $1,208,500 | ||||||
| Shares issued and restricted stock units ("RSUs") vested under stock option plan | 762,955 | 1,940 | (1,606) | – | – | 334 | ||||||
| Share-based compensation expense | – | – | 16,399 | – | – | 16,399 | ||||||
| Foreign currency translation adjustment | – | – | – | – | 122 | 122 | ||||||
| Net loss | – | – | – | (30,528) | – | (30,528) | ||||||
| Balances as of June 30, 2023 | 289,189,469 | $744,756 | $96,423 | $355,547 | $(1,899) | $1,194,827 | ||||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.